-
公开(公告)号:EP4433160A1
公开(公告)日:2024-09-25
申请号:EP22840844.9
申请日:2022-11-16
发明人: MACDONALD, Brian , QUISEL, John , SAVAGE, Will , YANG, Hua , YU, Jonathan , WU, Min , BECONI, Maria , PEREZ, Jennifer, M. , MUELLER, Bernhard , POPP, Andreas
IPC分类号: A61P7/06 , C07K16/22 , C07K16/28 , A61K39/395
CPC分类号: A61K2039/50520130101 , C07K16/28 , C07K16/22 , C07K2317/7620130101 , A61P7/06 , C07K2317/2420130101 , A61K39/395
-
公开(公告)号:EP4430038A1
公开(公告)日:2024-09-18
申请号:EP22834767.0
申请日:2022-11-10
发明人: BOGDAN, Andrew , FARNEY, Elliot, P. , FROST, Jennifer, M. , KYM, Philip, R. , XIONG, Zhaoming , BARTON, Naomi, Anne , CARIOU-MUMFORD, Claire Anne Marie , MCMAHON, Christopher, Patrick , NANO, Giuseppe
IPC分类号: C07D417/04 , C07D417/14 , A61K31/433
CPC分类号: C07D417/14 , C07D417/04
-
公开(公告)号:EP4403223A2
公开(公告)日:2024-07-24
申请号:EP24151934.7
申请日:2015-06-05
申请人: AbbVie Inc.
IPC分类号: A61P31/14
CPC分类号: C07K5/0827 , C07K5/0808 , A61K38/06 , A61P31/14 , A61P43/00
摘要: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of Figures 1-4.
-
公开(公告)号:EP4364754A2
公开(公告)日:2024-05-08
申请号:EP24151653.3
申请日:2017-06-07
申请人: AbbVie Inc.
发明人: BENATUIL, Lorenzo , BRUNCKO, Milan , CHAO, Debra , IZERADJENE, Kamel , JUDD, Andrew S. , PHILLIPS, Andrew C. , SOUERS, Andrew J. , THAKUR, Archana
IPC分类号: A61K39/00
CPC分类号: A61K2039/50520130101 , C07K2317/2420130101 , C07K2317/3320130101 , C07K2317/5220130101 , C07K2317/9220130101 , C07K2319/5520130101 , A61K31/437 , A61K31/498 , A61K31/519 , A61K47/6877 , A61K47/6803 , A61K47/6849 , C07K16/2827 , C07K2317/3420130101 , C07K2317/5620130101 , C07K2317/56520130101 , C07K2317/7620130101 , A61P35/00 , A61P43/00
摘要: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号:EP3704089B1
公开(公告)日:2023-07-19
申请号:EP18811983.8
申请日:2018-11-02
发明人: MARTIN, Kathleen, Ann , SIDRAUSKI, Carmela , PLIUSHCHEV, Marina, A. , FROST, Jennifer, M. , TONG, Yunsong , XU, Xiangdong , SHI, Lei , ZHANG, Qingwei , XIONG, Zhaoming , SWEIS, Ramzi, Farah , DART, Michael, J. , MURAUSKI, Kathleen
IPC分类号: C07C233/00 , C07C235/00 , C07C237/00 , C07D213/40 , C07D213/65 , C07D213/71 , C07D213/75 , C07D213/84 , C07D231/12 , C07D241/12 , C07D241/20 , C07D471/04 , C07D261/08 , C07D263/32 , C07D271/06
-
公开(公告)号:EP3452453B1
公开(公告)日:2022-04-13
申请号:EP17724209.6
申请日:2017-05-05
发明人: SIDRAUSKI, Carmela , PLIUSHCHEV, Marina , FROST, Jennifer, M. , BLACK, Lawrence, A. , XU, Xiangdong , SWEIS, Ramzi, Farah , SHI, Lei , ZHANG, Qingwei , TONG, Yunsong , HUTCHINS, Charles, W. , CHUNG, Seungwon , DART, Michael, J.
IPC分类号: C07D231/12 , C07D237/08 , C07D239/34 , C07D241/12 , C07D471/04 , C07D261/08 , C07D263/32 , C07D271/07 , C07D277/28 , C07D209/14 , C07D213/40 , C07D213/64 , C07D307/52 , A61K31/4402 , A61P35/00
-
公开(公告)号:EP3733180A1
公开(公告)日:2020-11-04
申请号:EP20167304.3
申请日:2014-03-14
申请人: AbbVie Inc.
发明人: BERNSTEIN, Barry M. , DUTTA, Sandeep , LUI, Wei , PODSADECKI, Thomas J. , CAMPBELL, Andrew L. , MENON, Rajeev M. , LIN, Chih-Wei , WANG, Tianli , AWNI, Walid M. , MENSING, Sven
IPC分类号: A61K31/454 , A61K31/4985 , A61K31/7056 , A61K45/06 , A61P31/14 , A61P1/16
摘要: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:EP2691134B2
公开(公告)日:2020-10-07
申请号:EP12713552.3
申请日:2012-03-29
申请人: AbbVie Inc.
发明人: RAO, Vivek , SHANG, Sherwin , OZDARYAL, Esra , TSVIRKO, Eduard , CHIM, Edwin , POST, David , DIPALMA, Vincent
-
公开(公告)号:EP3710428A1
公开(公告)日:2020-09-23
申请号:EP18811984.6
申请日:2018-11-02
发明人: MARTIN, Kathleen, Ann , SIDRAUSKI, Carmela , FROST, Jennifer, M. , PLIUSHCHEV, Marina, A. , TONG, Yunsong , BLACK, Lawrence, A. , XU, Xiangdong , SHI, Lei , ZHANG, Qingwei, I. , CHUNG, Seungwon , SWEIS, Ramzi, Farah , DART, Michael, J. , RANDOLPH, John, T. , MURAUSKI, Kathleen
IPC分类号: C07D213/74 , C07C255/57 , C07D231/14 , C07D237/10 , C07D241/12 , C07D241/44 , C07D261/08 , C07D235/14 , C07D307/56 , C07D307/82 , C07D317/62 , C07D401/04 , C07D413/04 , C07D487/04 , C07D275/03 , C07D495/04 , C07D513/04 , C07D213/54 , A61P35/00 , A61K31/165
-
公开(公告)号:EP3680253A2
公开(公告)日:2020-07-15
申请号:EP20150745.6
申请日:2011-02-28
申请人: AbbVie Inc.
IPC分类号: C07K16/18
摘要: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
-
-
-
-
-
-
-
-
-